Axcella Therapeutics presents results from Phase 2a clinical trial of AXA1125 for treatment of Long COVID Fatigue
Axcella Therapeutics presents results from Phase 2a clinical trial of AXA1125 for treatment of Long COVID Fatigue Axcella Therapeutics – a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions – gave two oral presentations of results from the Phase 2a clinical trial of AXA1125 in the […]
